ANI PHARMACEUTICALS INC - Common Stock (ANIP)

CUSIP: 00182C103

Q1 2026 13F Holders as of 31 Mar 2026

Holder snapshot 7 signals
Share change
+1,891,567
Put/Call ratio
206%
SEC-reported price per share
$76.90
Number of holders
278
Value change
+$144,062,603
Number of buys
145
Open additional details 1 more signal available
Number of sells
127
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
22,655,023

Security key

00182C103

Report period

Q1 2026

Institutions

278

Top holders

10

Ownership snapshot

Top reported holders of ANIP - ANI PHARMACEUTICALS INC - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Meridian Venture Partners...
Disclosed value leader
BlackRock, Inc.
Comparable rows
15/15
Latest evidence
13 Mar 2026
13D/G 13F 3/4/5 Lead comparable stake: 4.8% 13D/G row: Meridian Venture Partners II GP, L.P. Showing 1-6 of 15 holder rows.

Quick read

Meridian Venture Partners II GP, L.P. leads the comparable SEC ownership view at 4.8%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Meridian Venture Partners II GP, L.P.'s linked filing trail.
Comparable ownership Top 5
Meridian Venture Partners II GP, ... 4.8%
MILLENNIUM MANAGEMENT LLC 3.8%
INTEGRATED CORE STRATEGIES (US) LLC 0.3%
Muthusamy Shanmugam 2.4%
Chad Gassert 1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Meridian Venture Partners II GP, L.P.
13D/G
Robert E. Brown, Jr.
4.8%
$66,419,394
1,034,570 shares
-$9,630,000 21 Aug 2025
MILLENNIUM MANAGEMENT LLC
13D/G 13F
Company
3.8%
$57,136,569
818,341 shares
-$19,037,261 31 Mar 2025
INTEGRATED CORE STRATEGIES (US) LLC
13D/G
Millennium Management LLC
0.3%
$5,976,442
65,245 shares
-$96,309,614 30 Sep 2025
Muthusamy Shanmugam
3/4/5
HEAD OF R&D, COO-NOVITIUM OPS, Director
2.4%
$44,650,672
537,976 shares
-$17,860,541 26 Feb 2026
Chad Gassert
3/4/5
SVP - CORP. DEV. & STRATEGY
1%
$18,904,923
233,406 shares
-$3,051,835 26 Feb 2026
Christopher Mutz
3/4/5
HEAD OF RARE DISEASE
0.4%
$6,541,376
91,309 shares
-$1,635,601 13 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
278
Shares
23,377,686
Rows available
278
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q1 2026 Across Filers

Q1 2026 holders
278
Q1 2026 holders
278
Holder diff
0
Investor Q1 2026 Shares Q1 2026 Shares Share Diff Share Chg % Q1 2026 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .